PPTDF.US PeptiDream Inc
- Market cap
- USD 861M
- P/E
- -
- P/B
- 2.83x
- ROE
- -6.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PPTDF.US undervalued?
Graham numberThe Graham number of PeptiDream Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PeptiDream Inc fundamental analysis
No fundamental analysis for PeptiDream Inc yet.
PeptiDream Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PeptiDream Inc
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug discovery platform that integrates the technologies to synthesize highly diverse macrocyclic peptide libraries and screen for hit compounds, as well as enables rapid and efficient identification of novel hit compounds wi…
Full company profilePeptiDream Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PeptiDream Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.90B | 6.43B | 7.22B | 7.22B | 11.7B | 9.37B | 26.9B | 28.7B | 46.7B | 18.5B | 19.8B |
| Gross Profit | 3.54B | 4.65B | 5.57B | 5.57B | 9.53B | 7.01B | 18.1B | 17.2B | 34.5B | 7.53B | 9.32B |
| Operating Income | 2.49B | 2.91B | 3.58B | 3.58B | 6.99B | 4.42B | 8.98B | 6.77B | 21.1B | -4.98B | -3.80B |
| EBITDA | 2.69B | 3.43B | 4.10B | 4.10B | 8.52B | 5.00B | 10.9B | 9.04B | 23.8B | -2.85B | -1.83B |
| Net Income | 1.89B | 2.34B | 2.77B | 2.77B | 4.45B | 3.61B | 7.55B | 3.04B | 15.0B | -3.75B | -3.15B |
| EPS | 15 | 18 | 21 | 21 | 34 | 28 | 58 | 23 | 116 | -29 | -25 |
| Balance Sheet | |||||||||||
| Total Assets | 13.6B | 16.5B | 20.0B | 17.8B | 26.3B | 26.6B | 63.9B | 69.5B | 92.8B | 77.1B | 71.5B |
| Total Liabilities | 1.45B | 1.79B | 2.59B | 839M | 5.05B | 1.62B | 31.8B | 29.1B | 36.0B | 25.5B | 23.0B |
| Shareholders' Equity | 12.2B | 14.7B | 17.4B | 17.0B | 21.2B | 25.0B | 32.0B | 40.3B | 56.8B | 51.6B | 48.4B |
| Cash & Short-term Investments | 6.56B | 3.51B | 6.85B | 6.99B | 7.15B | 11.7B | 5.25B | 19.5B | 48.1B | 28.7B | 20.4B |
| Total Debt | - | - | - | - | - | - | 21.0B | - | 19.6B | 17.1B | 15.1B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.53B | 1.02B | 4.48B | 4.48B | 1.73B | 6.65B | -82.9M | 12.4B | 23.8B | -13.3B | -5.05B |
| Capital Expenditure | 1.93B | 2.47B | 195M | 195M | 586M | 1.21B | 3.98B | 1.37B | 2.22B | 1.64B | 1.48B |
| Free Cash Flow | -404M | -1.45B | 4.29B | 4.29B | 1.15B | 5.44B | -4.06B | 11.1B | 21.6B | -14.9B | -6.54B |
| Ratios | |||||||||||
| ROE | 15.5% | 15.9% | 15.9% | 16.3% | 21.0% | 14.4% | 23.6% | 7.5% | 26.5% | -7.3% | -6.5% |
| ROA | 13.9% | 14.2% | 13.8% | 15.5% | 16.9% | 13.5% | 11.8% | 4.4% | 16.2% | -4.9% | -4.4% |
| Net Profit Margin | 38.6% | 36.3% | 38.4% | 38.4% | 38.1% | 38.5% | 28.1% | 10.6% | 32.2% | -20.2% | -15.9% |
| Debt to Equity | - | - | - | - | - | - | 0.66x | - | 0.35x | 0.33x | 0.31x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
PeptiDream Inc dividends
PeptiDream Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 2:1 on Jun 28, 2017.
Who owns PeptiDream Inc
- Insiders 26.58%
- Institutions 36.01%
- Public & others 37.41%
- Shares outstanding 129M
- Free float 95.4M
PeptiDream Inc company profile
- Company name
- PeptiDream Inc
- Ticker
- PPTDF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 645
- Fiscal year end
- December
- Address
- 3-25-23 Tonomachi, Kawasaki, Japan, 210-0821
- Phone
- 81 4 4270 1300
- Website
- peptidream.com
About PeptiDream Inc
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug discovery platform that integrates the technologies to synthesize highly diverse macrocyclic peptide libraries and screen for hit compounds, as well as enables rapid and efficient identification of novel hit compounds with high potency and selectivity for protein targets in drug discovery campaigns. It is developing 64Cu-ATSM indicated for malignant brain tumor; and 177Lu/64Cu-PSMA I&T indicated for prostate cancer that are in phase 3 clinical phase development stage, as well as GhR Antagonist indicated for acromegaly that is in phase 2 clinical phase development stage. The company also develops 225Ac/68Ga-GPC3 indicated for hepatocellular carcinoma; 177Lu/68Ga-FAP indicated for pancreatic, lung, breast, colon cancer; 225Ac/64Cu-CA9 indicated for renal cell carcinoma; 18F-PD-L1 indicated for cancer; CD38-ARM indicated for multiple myeloma; S2-protein inhibitors indicated for COVID-19; and merck that are in phase 1 clinical phase development stage. In addition, it develops novartis and rayzeBio indicated for cancer, 225Ac/64Cu-CLDN18.2 indicated for stomach cancer, 225Ac/177Lu/64Cu/68Ga-CDH3 indicated for head and neck cancer, KIT inhibitors indicated for allergic diseases, oral myostatin inhibitors indicated for obesity/muscle disease, and Oral IL-17A/F inhibitors indicated for inflammatory diseases such as psoriasis that are currently under preclinical development stage. Further, the company involved in research, development, manufacture and sale of pharmaceuticals in the fields of radiopharmaceuticals (RI) and non-RI. PeptiDream Inc. was incorporated in 2006 and is based in Kawasaki, Japan.
PeptiDream Inc management
8- Dr. Patrick Crawford Reid Ph.D.President, CEO & Representative Director · born 1975
- Ms. Kaseri Oura M.S., P.M.P.Executive Vice President of Operations · born 1975
- Mr. Christian Cunningham Ph.D.Chief Scientific Officer
- Ms. Yuko OkimotoIR & Public Relations Director
- Mr. Kodo Shikata Ph.D.Executive Vice President of People & Culture
- Mr. Masato Murakami M.B.A., M.D., Ph.D.Executive VP of Radiopharmaceuticals Business, Chief Medical Officer & Director · born 1974
- Dr. Yen Ting Chen Ph.D.Head of Business Development & Alliance Management
- Mr. Jun Kono M.B.A.Executive Vice President of Strategy